Mechanisms of actin-binding proteins in glycolysis-cytoskeleton coupling Authors: Ziluo Zhang, Ningye Ma, Nan Zhang, Xinjia Wang, Yiwei Lu, Chengcheng Sheng, Jiantong Zhang, Xianghan Zhao, Yisheng Jiao, Aiyuan Wang Published: 2026 ABSTRACT AbstractBackgroundThe spatiotemporal coordination between actin cytoskeleton dynamics and glycolytic metabolism represents a critical frontier at the intersection of mechanobiology and cellular metabolism. While a bidirectional relationship between these processes is increasingly recognized, the underlying mechanistic coupling—particularly the role of actin-binding proteins (ABPs)—remains incompletely understood. This knowledge gap significantly limits our comprehensive understanding of mechano-metabolic cross-regulation.Main contentHere, we synthesize recent advancements in cytoskeletal dynamics and metabolic regulation to propose an ABP-mediated “metabolism-cytoskeleton” bidirectional coupling axis as a conceptual framework. By delineating the signaling cascades within this framework, we critically examine how ABPs function as key mediators that coordinate cytoskeletal remodeling with glycolytic flux in specific cellular contexts. Furthermore, we highlight recent mechanistic insights, evaluate prevailing controversies, and identify unresolved scientific questions that warrant future investigation.ConclusionThe proposed bidirectional “metabolism-cytoskeleton” feedback model conceptualizes the continuum from extracellular mechanotransduction to terminal cellular behavior. By expanding upon traditional unidirectional models, this framework provides a conceptual scaffold for understanding mechano-metabolic crosstalk. Additionally, it explores potential context-dependent therapeutic implications for diseases characterized by aberrant cytoskeletal and metabolic states, such as specific models of cancer and fibrosis.Keywords: Actin-binding protein, Glycolysis, Cytoskeleton of cells Introduction Eukaryotic processes—including proliferation, directed migration, invasion, differentiation, and tissue homeostasis—rely on the coordinate integration of extracellular mechanical cues and intracellular nutrient availability. Central to these phenotypic adaptations are two interactive systems: the dynamic plasticity of the actin cytoskeleton and the rewiring of cellular metabolic networks. Rather than functioning merely as a static structural scaffold, the actin cytoskeleton serves as a primary hub for cellular mechanical sensing and mechanotransduction. This highly dynamic actin remodeling imposes a spatiotemporally localized demand for ATP. Because mitochondrial oxidative phosphorylation is often constrained by intracellular diffusion barriers, glycolysis—a rapid, mitochondria-independent ATP-generating pathway—plays a key role in fueling rapid cytoskeletal dynamics by enabling localized ATP synthesis. Propelled by recent advancements in super-resolution imaging and single-cell metabolic flux analyses, emerging evidence suggests that cytoskeletal remodeling and glycolytic rewiring are physically and functionally linked. The dysregulation of this mechano-metabolic interplay is increasingly recognized as a potential driver in the progression of complex diseases, notably cancer and fibrosis. In this review, we systematically dissect the molecular mechanisms, regulatory networks, and biological functions underlying this mechanometabolic axis. We critically evaluate the coupling between actin-binding proteins (ABPs) and metabolism across five specific levels: (1) direct physical interactions, (2) spatial metabolic compartmentalization, (3) mechanochemical feedback loops, (4) metabolite-driven epigenetic and signaling regulation, and (5) translational potential in disease. Finally, we dialectically analyze the unresolved scientific questions shaping the future of this evolving field. Background: integration of ABP-mediated cytoskeletal dynamics with localized glycolysis Roles and functional classification of actin-binding proteins (ABPs) As key regulators of cell migration, actin-binding proteins (ABPs) are integrated into a range of biological processes. By interacting with actin monomers or filaments, this diverse protein superfamily orchestrates the dynamic assembly and spatial organization of the actin cytoskeleton. Through the modulation of steps such as actin nucleation, polymerization, cross-linking, severing, and depolymerization, ABPs regulate events including morphogenesis, motility, and signal transduction [1]. Rather than acting solely as structural scaffolds, ABPs can function as dynamic mechanotransducers. They convert biochemical cues into mechanical responses via conformational shifts, enzymatic regulation, and liquid-liquid phase separation [2], thereby regulating spatiotemporal cytoskeletal behavior. Consequently, the dysregulation of ABPs is frequently observed during oncogenesis and tumor progression. The pro-tumorigenic-like roles of ABPs typically manifest through remodeling the actin cytoskeleton to facilitate cancer cell invasion [3, 4]; or perturbing apoptotic pathways to support cell proliferation [5]. Given that aberrant ABP expression often correlates with malignant progression, ABPs are being investigated as potential diagnostic or prognostic biomarkers [6]. Based on their roles in actin dynamics, ABPs are broadly categorized into distinct functional modules: nucleating factors (e.g., the Arp2/3 complex) that initiate new filament assembly [7]; cross-linking and bundling proteins (e.g., Fascin and α-Actinin) that provide mechanical rigidity [8, 9]; turnover regulators (e.g., Profilin and Cofilin/ADF) that facilitate actin depolymerization to maintain a dynamic equilibrium [10–12]; anchoring proteins (e.g., ERM family and Vinculin) that physically link the actin network to the plasma membrane [13, 14]; and motor proteins (e.g., Myosin) that generate contractile forces [15]. Figure 1 delineates these major ABP families according to their primary effects on actin nucleation, stabilization, turnover, anchoring, and force generation, thereby establishing the structural framework for the metabolic coupling paradigms discussed throughout this review. Ultimately, a comprehensive elucidation of ABP functional mechanisms will not only advance our fundamental understanding of cell motility, morphological plasticity, and signal integration, but also provides clues to decode the complex molecular basis of tumor metastasis. Moreover, the correlation of ABPs with tumors, while not representing a direct pro‑tumorigenic mechanism, possesses clinical translational value. Functional classification of actin binding proteins and their roles in cytoskeletal remodeling Regulated glycolysis as a localized bioenergetic driver for cytoskeletal dynamics Far from being a rudimentary pathway for glucose degradation, glycolysis operates as a highly orchestrated, multi-enzymatic cascade compartmentalized within specific subcellular microdomains. At its core, this pathway governs the sequential transfer of free energy and precisely modulates the flux of metabolic intermediates across ten enzymatic steps, thereby generating a highly dynamic metabolic microenvironment within the cytosol [16, 17]. Concurrently, cytoskeletal dynamics act as the quintessential biophysical drivers that sustain morphological plasticity, propel directional cell migration, and mediate mechanotransduction. The continuous remodeling of the cytoskeletal architecture is critically dependent on the rapid hydrolysis of ATP and GTP [18], establishing a tightly coupled biochemical-mechanical system. Cell migration, in particular, underpins critical physiological and pathological events ranging from tissue repair and immune surveillance to tumor metastasis, with its kinetic efficiency strictly contingent upon an immediate and localized supply of ATP [19]. Exhibiting an ATP production rate up to 10 [4] times faster than oxidative phosphorylation, coupled with the strategic subcellular compartmentalization of its metabolic enzymes [20], glycolysis emerges as the predominant bioenergetic pathway propelling cell motility. Crucially, this metabolic preference is not merely a serendipitous byproduct of the Warburg effect, but rather an evolutionarily conserved and meticulously regulated adaptive strategy [21]. Consequently, under pathological conditions, the dysregulation of glycolytic flux precipitates aberrant cell migratory behaviors; thus, therapeutically targeting the spatiotemporal dynamics of glycolysis is rapidly emerging as a promising paradigm for anti-metastatic interventions. Coupling of ABPs-mediated cytoskeletal dynamics to glycolytic metabolism Emerging evidence in cytoskeletal and metabolic research indicates a functional integration between the actin network and glycolysis. Several rate-limiting enzymes of the glycolytic pathway have been shown to physically interact with the actin cytoskeleton. This dynamic association provides an ordered spatial scaffold for the glycolytic cascade. By constructing localized metabolic microenvironments—often referred to as metabolons—this spatial compartmentalization can shorten the diffusion distance of intermediates and reduce off-target reactions. Conversely, the dynamic remodeling of the actin cytoskeleton mediated by ABPs is an ATP-intensive process, demanding immediacy, spatial specificity, and localized high ATP concentrations. Because bulk mitochondrial oxidative phosphorylation may not precisely match the highly localized energy demands of actin turnover, glycolysis emerges as a critical, in-situ energy source supporting cytoskeletal dynamics. Despite these insights, the reciprocal regulatory mechanisms between the cytoskeleton and glycolysis—particularly the role of ABPs in this system—are not fully elucidated. To conceptualize this mechano-metabolic crosstalk, we propose a bidirectional functional coupling model. In this framework, ABP-mediated cytoskeletal remodeling provides spatial scaffolds for key glycolytic enzymes. The assembly of these multi-enzyme complexes generates metabolic compartments, potentially optimizing both glycolytic flux and ATP availability. In turn, the locally synthesized ATP and metabolic intermediates support the adjacent dynamic reconstruction of the cytoskeleton, forming a functional loop: “cytoskeletal assembly – metabolic optimization – localized energy supply – cytoskeletal remodeling.” We propose this “metabolism-cytoskeleton” bidirectional axis as a conceptual framework for understanding how mechanometabolic homeostasis influences cellular phenotypes. Building upon this paradigm, we construct an integrated signaling cascade model (Fig. 2): extracellular mechanical input → ABPs-mediated cytoskeletal remodeling → glycolytic compartmentalization → metabolic flux reprogramming → metabolite-driven reverse regulation of mechanical sensing and actin dynamics → phenotypic determination. It is important to note that this pathway is assembled from partially overlapping observations across various models and has not yet been demonstrated end-to-end within a single biological system. As such, the model serves as a conceptual scaffold for future hypothesis-driven research rather than a completely validated description of a universal mechanism. To systematically evaluate the robustness of this field, we have stratified the literature into an evidence-calibrated matrix, which is synthesized at the conclusion of this review (see Table 1). Based on current evidence in specific cell types, ABPs appear to serve as promising mechanometabolic couplers integrating cellular mechanical sensing and glycolytic reprogramming, though the broad applicability of this role requires further investigation. Model of ABPs-mediated “metabolism-cytoskeleton " coupled pathways Table 1Evidence-calibrated matrix of the bidirectional mechanometabolic circuitManuscript SectionDirectly establishedSupported by convergent evidenceConceptual frameworkUnresolved questionDirect physical couplingPhysical binding of specific enzymes (PFK, ALD, GAPDH, PKM2) to F-actin and ABPs (e.g., Fascin, α-actinin) in specific in vitro, neuronal, and tumor models.“Filamentous scaffolding”: ABPs selectively stabilize multienzyme complexes on F-actin to preserve activity under stress (convergent in neurons and cancer cells).Physical scaffolding circumvents Brownian diffusion, allowing ABPs to act as allosteric modulators of enzyme kinetics and substrate affinity.Does this coupling extend to all glycolytic enzymes universally, or is it exclusive to rate-limiting steps?Specific mechanotransduction axes (e.g., Fascin/ITGB8, PGK1/MYH9) drive glycolytic shifts in cancer and endothelial systems.Reciprocal coordination: Localized actin remodeling (e.g., Arp2/3) is directly fueled by spatially tethered glycolytic ATP (e.g., in macrophages).Tethered enzymes exert non-catalytic “moonlighting” effects, forming a bidirectional, closed-loop feedback model.What is the specific molecular “switch” dictating an enzyme’s catalytic vs. structural (moonlighting) role?Do these localized interactions dictate global metabolic flux in vivo?Spatial metabolic organizationLiquid-liquid phase separation (LLPS) of enzymes (e.g., ALD-A, GAPDH) forms “glycolytic bodies” along F-actin in specific in vitro models.These condensates generate distinct, high-concentration microenvironments physically separated from the bulk cytosol.Metabolism shifts from a “homogeneous bulk network” to “spatially confined functional modules” (glycolytic metabolons).Are these context-dependent condensate dynamics a universal disease mechanism across diverse cell types?Specific ABPs (e.g., TPM4) mediate metabolic condensation under defined stress conditions (e.g., hyperosmotic stress).Spatial proximity of specific enzymes (e.g., GAPDH and LDH) sustains local coenzyme (NAD+/NADH) recycling and homeostasis.ABPs spatially couple energy production (metabolic channeling, local ATP) directly to sites of high cytoskeletal consumption (e.g., lamellipodia).Can mechanical tension be transduced through ABPs to allosterically modulate metabolon assembly and activity in vivo?Is LLPS in vivo actively driving—or merely correlative to—complex disease microenvironments?Mechanotransduction feedbackMacrophage stress relaxation rates dictate specific metabolic switching (rapid = OXPHOS; slow = glycolysis).Extracellular cues govern YAP nucleocytoplasmic shuttling to integrate biomechanical tension with glycolytic adaptation.“Outside-in” mechanometabolic circuit: External mechanical tension is transduced to spatiotemporally tune glycolytic enzyme transcription and subcellular assembly.Can this pieced-together bidirectional feedback loop be integrated and functionally validated within a single, complex 3D in vivo environment?Proteomic enrichment of enzymes (ALD, GAPDH) at Arp2/3 complexes fuels localized actin polymerization at leading edges.Myosin contractility activates the integrin-FAK-HIF-1α signaling axis, upregulating glycolysis to meet energetic demands.Cellular protrusions (e.g., lamellipodia) operate as specialized, mitochondria-independent “mechanometabolic microdomains”.Is chaperone-guided intracellular trafficking of metabolic enzymes via actomyosin networks a universal mechanism across all migratory cells?Microgravity (unloading) triggers RhoA-dependent actin depolymerization and compensatory glycolytic rewiring.Global stability of both actin and microtubule networks relies heavily on highly localized ATP/GTP availability and coenzyme (NAD+/NADH) redox homeostasis.The entire bidirectional feedback loop is currently a synthesized paradigm, assembled from distinct modular observations across separate models.Do glycolytic metabolites function as active signaling effectors to exert retrograde (“inside-out”) control over cellular mechanosensing?Metabolite mediated regulationATP depletion physically dissociates Fascin from leading-edge patches into multimeric actomyosin aggregates in vitro.The localized ATP/ADP ratio acts as a continuous “bioenergetic rheostat” governing ABP localization and cytoskeletal stability.Retrograde (“Inside-Out”) Axis: Glycolytic metabolites are not merely passive outputs; they function as active signaling effectors to modulate actin dynamics.Can extracellular glucose influence actin remodeling via a “metabolism-independent” mode (e.g., physical engagement with surface receptors transducing Rho-GTPase signals)?Pharmacological glycolytic uncoupling (2DG) reversibly disrupts Fascin/α-SMA crosslinked microfilaments.ABP-dependent cytoskeletal plasticity (e.g., perinuclear Fascin) relies specifically on localized glycolytic flux rather than mitochondrial OXPHOS.Three-tier regulatory logic: (1) ATP bioenergetic rheostat; (2) Glucose flux-dependent morphogenic control; (3) Covalent structural perturbation by reactive byproducts (MG).Do these discrete metabolite axes operate synergistically within complex 3D pathophysiological microenvironments?Methylglyoxal (MG) induces covalent post-translational adducts on actin/myosin, creating steric hindrance in specific diabetic models.ABP depletion (e.g., Cofilin-1, Profilin-1) triggers predictable, convergent compensatory shifts between glycolysis and OXPHOS/ROS.Diabetic cardiomyopathy is reframed from a systemic energetic deficit to a direct biomechanical breakdown of the metabolism-cytoskeleton interface.How can precise spatiotemporal signaling at this interface be targeted for therapeutic intervention in vivo?Disease translationHyperglycemia induces Profilin O-GlcNAcylation, dismantling the “GAPDH-Profilin-actin” unit and causing localized bioenergetic deficits in diabetic wound models.Chronic mechanical loading (e.g., ECM stiffness) persistently activates mechanometabolic reprogramming via conserved axes (e.g., TAGLN-RhoA/ROCK2-GLUT3 in fibrosis).Pathological Positive Feedback Loop: Structural aberrations or spatiotemporal uncoupling of the mechanometabolic circuit drive diverse diseases (malignancies, fibrosis, neurodegeneration).Can the in vitro disruption of phase-separated (LLPS) metabolons be translated in vivo without triggering significant systemic metabolic toxicity?Fascin inhibitors physically dismantle glycolytic metabolons within invadopodia, starving tumor cells and suppressing metastasis in TNBC models.Aberrant glycolytic flux enhances cellular contractility and vascular compromise (e.g., HK2-driven ROCK2-MLC2 activation in tumor pericytes).Disease as “Defective Nodes”: Rather than a unified etiology, diverse pathological hallmarks represent breakdowns at discrete junctions within the bidirectional continuum.How can pharmacological interventions achieve the necessary target specificity and localized spatiotemporal delivery within complex in vivo microenvironments?Small molecules targeting the LLPS interface of ALD-A/GAPDH selectively dissolve tumor-specific metabolons in vitro.Global energy dysfunction uniformly disrupts ATP/GTP balance, manifesting as phenotypic failures (mitotic catastrophes, axonal transport defects) across disparate disease models.Therapeutic Decoupling: Targeting specific nodes (e.g., mechanosensing or localized metabolons) offers a conceptual avenue for precision medicine.Can these preclinical paradigms be successfully translated into unifying diagnostic biomarkers and clinically viable therapies across disparate pathophysiological categories? Evidence-calibrated matrix of the bidirectional mechanometabolic circuit Direct physical coupling As potential mechanometabolic couplers linking actin cytoskeletal dynamics with glycolytic pathways, certain actin-binding proteins (ABPs) participate in a bidirectional “metabolism-cytoskeleton” axis. This network is proposed to rely on the physical tethering of specific glycolytic enzymes to the actin cytoskeleton. By potentially reducing reliance on Brownian diffusion, these protein-protein interactions may allow for the spatial anchoring of metabolic enzymes, providing a structural framework for mechanometabolic synchronization. This section delineates the molecular mechanisms observed in these interactions, synthesizes empirical evidence for enzyme-cytoskeleton binding, and evaluates how these scaffolds contribute to metabolic compartmentalization. ABPs and the modulation of specific glycolytic enzyme activities The activity of several key glycolytic enzymes appears to be sensitive to their association with the actin cytoskeleton. Phosphofructokinase (PFK), a rate-limiting enzyme of glycolysis, binds to filamentous actin in a concentration-dependent manner in several models [22]; this tethering has been observed to preserve PFK enzymatic tetramers under specific stress conditions, such as low pH or hypothermia [23]. Furthermore, studies indicate that actin binding to aldolase (ALD) may antagonize PFK-1 inhibition by ascorbate [24, 25], suggesting a regulatory node integrating flux with cytoskeletal state. Specific ABPs further refine this regulation. For instance, the bundling protein Fascin exhibits conformational plasticity that may increase its interaction interface with metabolic enzymes, potentially concentrating them to enhance catalytic turnover [26]. Similarly, α-actinin has been implicated in metabolic routing, as its deficiency in certain models impairs glycogen phosphorylase activity [27, 28]. Additionally, profilin 2 interacts with PKM2 and appears necessary for its nuclear translocation [29, 30], indicating that ABPs may govern intracellular trafficking alongside catalytic state. While interactions between ABPs and enzymes like PFK, ALD, and PKM2 are well-documented in specific cell types, it remains an unresolved question whether this regulatory mechanism extends to all ten enzymes of the glycolytic pathway or if it is a specialized feature of rate-limiting steps. ABPs as stabilizers of glycolytic multi-protein complexes Fascin serves as a primary model for understanding how ABPs stabilize metabolic machinery. Rather than interacting with monomeric G-actin, Fascin appears to selectively stabilize glycolytic multienzyme complexes on polymeric actin filaments [31]. The double-helical architecture of F-actin provides a topological scaffold that may facilitate multivalent binding, theoretically increasing the physical stability of these complexes compared to transient cytosolic interactions [1]. Empirical studies in various contexts have shown that Fascin can tether PFK, ALD, GAPDH, LDH, and ENO2 [32–36]. A clear example is found in neuronal axons, where GAPDH and actin form a reciprocal complex: GAPDH acts as a chaperone for G-actin translocation, while the filamentous network anchors GAPDH at high-energy-demand synaptic densities [37–39]. Similar co-localization has been observed in tumor cells, where the disruption of Fascin filaments correlates with the dissociation of PFK and a reduction in stress fibers [40–42]. To sum up, the principle of “filamentous scaffolding” is supported by convergent evidence in neurons and cancer cells. However, the exact biophysical “code” that determines which enzymes are recruited to specific ABP-actin bundles remains a hypothesis-generating area of research. Modulation of enzyme-substrate affinity via ABPs interaction Beyond spatial anchoring, ABPs may function as allosteric modulators. In vitro evidence suggests that Fascin increases the apparent affinity of PFK for its substrate, fructose-6-phosphate (F-6-P) [43]. This interaction may be responsive to external cues; for example, insulin signaling has been shown to promote the recruitment of PFK to actin-binding networks [44]. ABPs also influence enzyme availability through spatial sequestration. Fascin-bundled stress fibers can physically shield PFK platelet isoform (PFKP) from E3 ubiquitin ligases like TRIM21 by sequestering the ligase at the cell periphery, thereby extending the enzyme’s half-life [45]. Conversely, the C-terminal domain of Wiskott-Aldrich syndrome protein (WASp) competes with substrate binding for ALD, acting as a potential rheostat for glycolytic efficiency [46, 47]. These examples establish a conceptual framework for the cytoskeletal regulation of enzyme kinetics. However, the degree to which these competitive or allosteric interactions dictate global metabolic flux—versus localized adjustments—is not yet fully established. ABPs as integrators of mechanotransduction and glycolytic signaling ABPs often function as mechanosensory hubs, translating physical cues into metabolic shifts. Mechanical tension from the extracellular matrix can be transduced via the Fascin/ITGB8/TRIM59 axis to activate AKT-mTOR signaling, which is associated with increased glycolytic flux in tumor models [48]. Additionally, Fascin networks may influence YAP sequestration, creating a feedback loop that regulates HIF-1α mediated reprogramming [49]. Other ABPs exhibit similar signaling roles under stress. Under hypoxia, phosphoglycerate kinase 1 (PGK1) interacts with the motor protein MYH9 to stabilize transcriptional complexes like β-catenin/c-Myc, promoting a glycolytic feed-forward circuit [50]. In endothelial cells, RhoA signaling triggers a glycolytic burst through the activation of cofilin and myosin light chain (MLC) [51]. Collectively, the role of ABPs in mechanotransduction is directly established in specific cancer and endothelial systems. The generalizability of these signaling axes to healthy, non-migratory tissues remains an area for further investigation. Reciprocal regulation: glycolytic enzymes in actin remodeling The relationship between the cytoskeleton and metabolism is bidirectional, with glycolytic enzymes actively participating in actin remodeling. Increased ECM stiffness can trigger microfilament reorganization, which in turn recruits glycolytic enzymes to accommodate the energetic demands of remodeling [52–54]. Inhibition of glycolysis has been observed to blunt Fascin-mediated lamellipodial remodeling and suppress cell motility [26]. Proteins like the ADF/Cofilin family may act as molecular rheostats in this process; cofilin-mediated severing liberates G-actin, which then interacts with PFK and ALD-A to potentially fuel localized glycolytic bursts [11, 55–57]. This “closed-loop” feedback is further evidenced in macrophages, where PFK-derived ATP is linked to Arp2/3-driven pseudopodial extension [58]. This bidirectional feedback is a robust conceptual framework supported by multiple cell-migration studies. However, the precise molecular “switch” that shifts an enzyme from its catalytic role to its structural role (moonlighting) is not yet fully understood. Evolutionary and secondary messenger modulation The tethering between enzymes and the cytoskeleton is further refined by intracellular signals and evolutionary adaptations. In muscle fibers, Ca2+ fluctuations during contraction modulate the binding affinity of ALD for α-actinin, potentially synchronizing ATP production with mechanical work [59]. In Apicomplexan parasites, ALD serves as a physical bridge between adhesins and the actomyosin motor, a mechanism essential for host invasion [60, 61]. Furthermore, GAPDH may function as an energy sensor [62]; its autophosphorylation by ATP increases its affinity for F-actin, linking localized energy availability to cytoskeletal stability [63]. These specialized cases demonstrate that the mechanometabolic axis is evolutionarily conserved and sensitive to secondary messengers, though these mechanisms may be highly system-specific. In conclusion, the evidence reviewed supports the view that certain ABPs—notably Fascin and α‑actinin—function as active connectors between cytoskeletal dynamics and glycolytic regulation, rather than as passive scaffolds. Their physical coupling with glycolytic enzymes involves a tripartite mechanism: allosteric activation of rate‑limiting enzymes (established in specific systems), spatial scaffolding on F‑actin (supported by convergent evidence but not yet generalizable), and modulation of enzyme–substrate affinity (proposed conceptual framework). Reciprocally, tethered glycolytic enzymes may exert non‑catalytic moonlighting effects on actin turnover, suggesting a closed‑loop feedback model that remains to be fully validated. Figure 3 illustrates representative interaction modes such as enzyme stabilization, substrate accessibility modulation, signaling pathway integration, and reciprocal regulation of actin remodeling. Significant knowledge gaps persist regarding the in vivo spatiotemporal dynamics of this coupling in diseases such as fibrosis and cancer, and targeted interventions remain unexplored. Finally, the direct tethering described here is only the initial step, how it drives higher‑order metabolic compartmentalization is an unresolved question that will be examined in the next section. Molecular mechanisms underlying physical interaction between glycolytic enzymes and actin binding proteins Spatial metabolic organization The direct physical coupling between ABPs and key glycolytic enzymes extends beyond static protein-protein interactions; rather, it provides a structural basis for the spatiotemporal regulation of glycolysis. Characterized by specific and dynamic interactions, this physical tethering helps overcome the entropic constraints of stochastic cytoplasmic diffusion. It addresses the spatial topological challenges of coordinating multi-enzyme cascades by providing a dynamic scaffold for the ordered organization and localized enrichment of glycolytic enzymes. Ultimately, this leads to a proposed conceptual framework where these assemblies form functionally distinct microenvironments, often referred to as ABPs-mediated glycolytic metabolons. Classically, glycolysis was conceptualized as a linear process occurring within the bulk cytosol, where uniformly distributed enzymes rely on the stochastic free diffusion of substrates. However, emerging evidence has substantially revised this view, suggesting that ABPs participate in the spatial compartmentalization of the glycolytic pathway [64, 65]. This shift establishes a proposed conceptual framework for understanding mechanometabolic coupling, transitioning the view of cellular metabolism from a strictly “homogeneous reaction network” to one incorporating “spatially confined functional modules.” Within this model, it is hypothesized that the core function of specific ABPs is to anchor glycolytic enzymes to the dynamic actin network, integrating them into a unified “metabolism-cytoskeleton” module. To date, the most directly established evidence for this compartmentalization comes from specific in vitro and cellular models showing liquid-liquid phase separation (LLPS). Driven by the intrinsically disordered low-complexity domains of enzymes like ALD-A and GAPDH, these proteins have been observed to condense along actin filaments under specific conditions [66]. Notably, recent work identifying Tropomyosin 4 (TPM4) phase separation provides strong support for ABP-mediated metabolic condensation specifically within the context of hyperosmotic stress [67]. In these focused studies, this biophysical process leads to the formation of membraneless structures with metabolic activity, termed “glycolytic bodies.” While convergent evidence suggests these condensates generate high local concentrations of glycolytic machinery and physically distinct microenvironments from the bulk cytosol, extrapolating these context-dependent condensate dynamics as a universal disease mechanism across all cell types requires further mechanistic validation. The biological significance of this compartmentalized regulation is hypothesized to mediate three core functional enhancements, supported to varying degrees by current experimental models. First, it is proposed that scaffold proteins physically approximate sequential enzymes (e.g., ALD-A and GAPDH). Evidence from specific assays indicates this proximity may facilitate metabolic channeling, allowing intermediate metabolites to be directed between active sites with reduced equilibration into the bulk cytosol [68]. This mechanism could potentially maximize localized catalytic flux while minimizing intermediate leakage. Second, convergent evidence supports the idea that these semi-closed metabolic spaces help maintain local coenzyme homeostasis. Because GAPDH activity is highly dependent on NAD⁺ as an electron acceptor, local NAD⁺/NADH ratios are rate-limiting [69]. Scaffolding GAPDH with NADH-regenerating enzymes (e.g., LDH) is thought to establish a localized coenzyme recycling system, sustaining rapid NAD⁺ replenishment. Third, as a hypothesis-generating concept, these compartments may physically tether ATP-generating machinery directly to subcellular sites of high bioenergetic demand. The dynamic turnover of the actin network—during processes like lamellipodial extension and focal adhesion dynamics—consumes substantial ATP. By tethering ATP-generating kinases (e.g., PFK, PKM2) via specific ABPs (e.g., Fascin, α-actinin), models suggest cells can spatially couple energy production and consumption [70]. This localized ATP pool could be rapidly utilized by adjacent actin-nucleating sites. Furthermore, an unresolved but intriguing hypothesis posits that mechanical tension could be transduced through ABPs to allosterically modulate metabolon activity, matching bioenergetic supply to mechanical stress. In conclusion, ABPs-mediated glycolytic compartmentalization represents an important conceptual development in metabolic regulation, shifting focus toward spatially confined, localized processing. Through mechanisms such as condensate formation at sites of structural remodeling, ABPs are proposed to optimize substrate channeling, redox homeostasis, and energy transfer. However, a clear evidentiary boundary must be maintained: while advanced imaging technologies have directly validated spatiotemporal compartmentalization in vitro and in specific stress models, characterizing its general pathophysiological significance in vivo remains a largely unresolved question. Crucially, the direct causal links between phase separation, precise local metabolic flux alterations, and their discrete ABP dependencies in vivo reflect an ongoing scientific challenge. Future research must systematically decode the mechanosensitive assembly dynamics of these condensates and elucidate whether this bidirectional mechanometabolic cross-talk is actively driven by—or merely correlative to—complex disease microenvironments (e.g., tumor invasion, tissue fibrosis). Mechanotransduction feedback Building upon the paradigm that ABP-orchestrated glycolytic compartmentalization provides localized bioenergetics for cytoskeletal dynamics, we propose that this spatial organization may constitute the hub of a bidirectional metabolic-cytoskeletal feedback loop. Within this framework, glycolytic output is thought to exert a bipartite regulatory effect: providing the ATP required for actin polymerization under hyperosmotic stress conditions [67] while metabolic intermediates interact with ABPs [71] to influence the topological architecture and biomechanics of the network. Reciprocally, external biophysical cues—such as extracellular matrix (ECM) stiffness and tensile stretch—are transduced across the plasma membrane via mechanosensors (e.g., integrins) to modulate the glycolytic machinery. This “outside-in” mechanotransduction appears to tune the transcriptional expression and subcellular assembly of glycolytic enzymes, aiding the spatiotemporal regulation of metabolic flux [72, 73]. While these mechanisms represent a significant frontier in mechanobiology, it should be noted that this bidirectional metabolic-cytoskeletal feedback loop remains a conceptual framework synthesized from multiple studies. It is often pieced together from overlapping observations across different cell types and has yet to be validated within a single experimental system. This section delineates how the intracellular mechanical environment influences glycolytic feedback across three dimensions: (1) metabolic reprogramming driven by whole-cell tension; (2) localized mechanometabolic coupling within migratory protrusions; and (3) regulatory cross-talk between the microtubule and actin networks. Regulatory effects of global cellular mechanical tension on glycolytic metabolism Global mechanical forces dictate whole-cell metabolic reprogramming in several specific biological contexts. For instance, in germ cells, mechanical stress has been shown to govern cytoplasmic Ca2+ homeostasis via mechanosensitive ion channels [74]; which subsequently orchestrates metabolic transitions during development. Beyond ion flux, global cytoskeletal tension can drive nuclear deformation to influence the nucleocytoplasmic shuttling of YAP [75]—a mechanosensor that integrates biomechanical cues with glycolytic adaptation to regulate cell proliferation and differentiation. Furthermore, the viscoelastic properties of the cellular environment impose distinct bioenergetic demands. In certain macrophage models, the rate of mechanical stress relaxation acts as a biophysical switch: rapid relaxation is associated with oxidative phosphorylation, whereas slow relaxation correlates with the upregulation of rate-limiting glycolytic enzymes [76]. Conversely, microgravity—a paradigm of mechanical unloading—disrupts cellular architecture by inducing RhoA-dependent actin depolymerization. To mitigate the resulting bioenergetic stress, evidence suggests cells initiate a compensatory metabolic rewiring characterized by increased glycolytic flux and the suppression of fatty acid β-oxidation [77]. “Metabolic-skeleton” coupling mechanism of the core structural pseudopodia of cell polarization migration Cellular protrusions (e.g., lamellipodia and pseudopodia) operate as specialized mechanometabolic microdomains. Proteomic studies of these leading-edge structures reveal an enrichment of cytoskeletal networks, glycolytic enzymes (e.g., ALD and GAPDH), and molecular chaperones [78]. This clustering provides the architectural basis for localized mechanometabolic coupling. Bioenergetically, certain glycolytic enzymes have been observed to tether to the Arp2/3 complex, potentially assembling in situ ATP-generating metabolons. This localized grid is thought to fuel actin polymerization at the leading edge, compensating for the limited presence of mitochondria in these extremities [79]. Consistent with this model, the pharmacological inhibition of glycolysis has been shown to impair lamellipodial extension in vitro [80]. In angiogenic models, glycolytically derived ATP appears necessary for filopodial assembly and the modulation of intercellular adhesion [81]. Beyond catalysis, some glycolytic enzymes exhibit non-catalytic “moonlighting” functions. For example, GAPDH has been observed to co-localize with leading-edge β-actin, where it may stabilize polymerization sites during tumor cell migration [82]. Similarly, the sequestration of phosphohexose isomerase [83](PHI) and the shared epitopes between triosephosphate isomerase [84] (TIM) and filamin C suggest a structural role for metabolic enzymes in scaffold assembly. Molecular chaperones, such as heat shock proteins, are proposed to guide the trafficking of these enzymes via actomyosin networks [85], though the universality of this mechanism across all migratory cells remains an active area of investigation. Co-regulation of microtubule and microfilament cytoskeletal networks The dynamics of distinct cytoskeletal networks are linked to specialized metabolic cycles. The treadmilling of actin microfilaments is driven by the intrinsic ATPase activity of actin monomers, where ATP hydrolysis dictates the equilibrium between extension and depolymerization [86]. T To sustain this, cells coordinate glycolytic efflux; for example, the extrusion of lactate via monocarboxylate transporters helps preserve intracellular NAD+/NADH redox homeostasis [87, 88]. Because NAD+ replenishment is required for GAPDH-mediated catalysis, this balance is a key factor in maintaining uninterrupted glycolytic flux [69]. Parallel dependencies exist within the microtubule network, where “dynamic instability” is regulated by GTP hydrolysis [89]. While microtubules consume GTP locally, their global stability is often tethered to the overall energy status of the cell [90, 91]; in several models, high ATP levels correlate with ordered microtubule arrays, while bioenergetic depletion leads to network disintegration [92, 93]. This crosstalk extends to supramolecular assemblies like myofibrils, where the ionic environment acts as a rheostat. For instance, Mg2+ depletion can blunt glycolysis—as Mg2+ is a cofactor for glycolytic kinases—prompting an adaptive shift toward fatty acid β-oxidation [94]. Finally, the mechanical work of myosin motors, which transduces chemical energy into tension, can activate the integrin-FAK signaling axis [95] to influence the transcription factor HIF-1α [96]. This cascade potentially upregulates glycolytic machinery to meet the energetic demands of contractility, suggesting a self-reinforcing mechanometabolic loop. In summary, this section has synthesized a conceptual framework for the “outside-in” axis of the mechanometabolic circuit, exploring how biophysical cues may coordinate glycolytic reprogramming through intracellular tension, localized coupling in protrusions, and actin-microtubule crosstalk. This model is supported by direct evidence regarding specific regulatory components, such as Ca2+/Rho-GTPase signaling cascades and the compartmentalized channeling of ATP at the leading edge. However, while these individual mechanisms are well-documented in specific experimental models, their integration into a seamless end-to-end pathway remains a proposed paradigm that requires further validation within complex 3D in vivo environments. Furthermore, the translation of mechanical stress into metabolic flux represents only the forward phase of this axis. The emerging hypothesis that glycolytic metabolites function as active signaling effectors to exert retrograde (“inside-out”) control over mechanosensing remains an unresolved question that serves as the final link in the closed-loop circuit; this will be evaluated in the following section. Metabolite mediated regulation While the preceding sections have discussed the anterograde “outside-in” axis—wherein extracellular mechanical cues influence cytoskeletal remodeling to calibrate metabolic flux—the homeostasis of this bidirectional loop likely involves more than the passive bioenergetic output of glycolysis. It is proposed as a conceptual framework that intracellular metabolites generated throughout the glycolytic cascade may function as signaling effectors, contributing to the retrograde (“inside-out”) modulation of actin dynamics. By synchronizing with forward mechanosensing pathways, this metabolite-driven reverse regulation is hypothesized to forge integrated mechanometabolic microdomains, aiding cells in polarization, migration, and phenotypic adaptation. This section examines these retrograde coupling mechanisms across three dimensions: (1) the bioenergetic and signaling functions of ATP; (2) the cytoskeletal effects associated with glucose; and (3) the regulatory roles of glycolytic intermediates. Localized energy supply regulation of ATP As the primary bioenergetic currency of the glycolytic cascade, the intracellular ATP/ADP ratio functions as a metabolic rheostat [97]. The dynamic treadmilling of the actin cytoskeleton imposes bioenergetic demands that are coupled to this metabolic network [98]. Evidence established in specific systems demonstrates that perturbations in this energetic balance influence ABP-mediated cytoskeletal architecture. For instance, in resting fast-twitch muscle, extramitochondrial ADP occupies actin-binding sites [99], whereas severe ATP depletion is associated with the aggregation of tight junction proteins into insoluble complexes [100]. Furthermore, acute bioenergetic collapse has been shown to induce cytoskeletal disassembly [67, 101]. This structural change is mechanistically linked to the behavior of the bundling protein Fascin: under ATP deprivation in specific models, Fascin dissociates from leading-edge patches and is sequestered into multimeric actomyosin aggregates [102]. Notably, the reliance of ABPs on glycolytic ATP appears specific. Perinuclear Fascin can drive cytoskeletal rearrangement even when oxidative phosphorylation (OXPHOS) is inhibited [78], suggesting that Fascin-coordinated plasticity relies heavily on localized glycolytic flux. This metabolic dependence extends to other core ABPs. Cofilin-1, for example, is reported to coordinate the stress-gated actin response during oxidative stress, and its genetic ablation leads to a compensatory upregulation of glycolysis [103, 104]. Similarly, Profilin-1 maintains metabolic compartmentalization [105]; its deletion in hematopoietic stem cells shifts metabolic programming from glycolysis toward mitochondrial OXPHOS, triggering reactive oxygen species (ROS) accumulation [106]. Beyond physical tethering, ATP fluctuations also indirectly influence cytoskeletal dynamics by modulating the transcriptional expression of regulators such as α-SMA [107] and Actl6a [108]. In macroscopic models, such as cardiomyocytes, vagus nerve stimulation has been shown to enhance glycolysis and ATP synthesis, thereby optimizing the structural integrity of α-actinin-positive myofibrils [109]. Together, these paradigms illustrate how ATP and its associated bioenergetic shifts exert profound reverse control over ABP-dependent cytoskeletal homeostasis. Metabolic flow-directing effect of glucose Glucose, as the primary substrate of glycolysis, influences cytoskeletal morphodynamics. Within the bioenergetic-dependent axis, continuous glycolytic flux is necessary for maintaining localized cytoskeletal architecture. In the endothelial cell model, pharmacological uncoupling of this flux using 2-deoxy-D-glucose (2DG) disrupts F-actin networks and impairs cellular motility [110, 111]. This migration arrest in HSCS is structurally related to the disruption of fascin-crosslinked microfilaments and α-SMA-positive actomyosin arrays [112]. Some studies suggest this cytoskeletal disruption may be reversible; the withdrawal of 2DG and restoration of glycolytic flux can reinstate actin assembly, highlighting a coupling between glucose availability and cytoskeletal turnover [113, 114]. Conversely, an emerging hypothesis-generating idea proposes a “metabolic-independent” mode, wherein extracellular glucose might influence actin remodeling independent of its catabolic fate [115]. In ovarian cancer cells, the physical engagement of glucose with surface transporters or receptors could transduce biophysical signals, potentially modulating core regulators like Rho-family GTPases to influence actin rearrangement [116]. However, the precise molecular mechanisms of these proposed glucose-sensing complexes require further empirical validation to be considered a generalizable pathway. Regulatory functions of other metabolites Beyond glucose and ATP, reactive intermediate byproducts of the glycolytic cascade can exert covalent control over cytoskeletal components. Notably, evidence established in specific disease models identifies the electrophilic dicarbonyl metabolite methylglyoxal (MG) as a structural disruptor. In models of diabetes mellitus, amplified intracellular MG accumulation is associated with increased covalent modification of sarcomeric elements, specifically actin and myosin. Rather than serving merely as biomarkers, these MG-induced post-translational adducts may act as biomechanical perturbations. Mechanistically, MG-mediated binding is thought to induce steric hindrance within the actomyosin complex, attenuating the binding affinity between myofilaments and regulatory proteins. This metabolite-driven alteration translates into impaired sarcomeric contractility. Ultimately, this MG-cytoskeleton axis offers a proposed molecular etiology for diabetic cardiomyopathy, framing it not only as a systemic energetic deficit but as a breakdown of the localized “metabolism-cytoskeleton” biomechanical interface [117]. In conclusion, current convergent evidence supports a conceptual framework wherein a retrograde axis of glycolytic metabolites actively contributes to cytoskeletal remodeling. Figure 4 depicts how ATP, glucose-derived intermediates, and associated metabolites may influence ABP activity and the feedback control of glycolytic flux. This regulatory logic is proposed to operate across three tiers: first, the localized ATP/ADP ratio functions as a bioenergetic rheostat governing ABP localization; second, glucose may exert morphogenic control via flux-dependent and potentially receptor-mediated pathways; and third, reactive byproducts like MG perturb actomyosin dynamics via post-translational modifications. While these examples are supported by convergent evidence in specific systems, unresolved questions remain before this can be considered a fully generalizable pathway. Deciphering the synergistic crosstalk among these regulatory axes within 3D pathophysiological microenvironments, decoding the precise spatiotemporal signaling at the “metabolism-cytoskeleton” interface, and validating targeted interventions represent key areas for future mechanobiological research. Metabolite driven regulation of cytoskeletal dynamics By integrating the molecular basis of direct ABP-glycolytic enzyme coupling, the structural scaffolding of metabolic compartments (metabolons), and mechanotransduction pathways, it is possible to propose a unified conceptual framework for the mechanometabolic circuit. This model suggests a sequence linking extracellular mechanical cues to phenotypic adaptation through several intermediate stages: mechanical input, cytoskeletal remodeling, glycolytic compartmentalization, metabolic flux reprogramming, and metabolite-driven retrograde feedback. Notably, while the individual components of this cascade are supported by evidence from various biological systems, this integrated pathway is a synthesis of partially overlapping examples rather than a mechanism demonstrated end-to-end within a single experimental model. The maintenance of this mechanometabolic balance appears important for physiological function. Its dysregulation is increasingly recognized as a potential factor in the pathogenesis and progression of diverse conditions, including malignancies, metabolic disorders, and tissue fibrosis. Building upon this foundational framework, the following section will explore the role of this regulatory network in disease pathophysiology. Furthermore, we will evaluate its potential translational significance, highlighting how targeting this mechanometabolic interface may offer novel therapeutic opportunities. Disease translation The previously established signaling continuum—spanning from mechanical input → ABP-driven cytoskeletal remodeling → metabolon assembly → flux reprogramming → metabolite-mediated retrograde feedback → phenotypic determination—represents a proposed conceptual framework for how eukaryotic cells might maintain mechanometabolic homeostasis. Under pathological conditions, it is hypothesized that structural or functional aberrations, spatiotemporal uncoupling, or the overactivation of individual nodes within this circuit can lead to “metabolism-cytoskeleton” dysregulation. This could potentially initiate a pathological positive feedback loop that drives the progression of diverse diseases, including malignancies, organ fibrosis, metabolic complications, and neurodegeneration. However, it is crucial to emphasize that the field has not yet established a unified pathophysiological or therapeutic framework across these disparate disease categories. Instead, current literature suggests that the pathological hallmarks of specific experimental models align with defective nodes within this proposed bidirectional model. First, converging evidence indicates that the chronic integration of aberrant mechanical cues can initiate a pathological cascade. Under physiological conditions, this loop appears to be triggered by the sensing of transient, moderate mechanical forces [118]. Conversely, in specific pathological microenvironments, persistent mechanical stress acts as a major driver for mechanometabolic reprogramming. For instance, in specific models of cutaneous fibrosis, ECM deposition increases tissue stiffness. This chronic mechanical loading persistently activates mechanosensors, driving disease progression via the TAGLN-RhoA/ROCK2-SLC2A3 axis. In this specific system, TAGLN stabilizes the actin network to elevate intracellular tension, further amplified by RhoA/ROCK2 signaling, which ultimately promotes the membrane translocation of SLC2A3 (GLUT3). This increases glycolysis to fuel the highly migratory phenotype of myofibroblasts. Consequently, pharmacological interventions targeting this axis may offer conceptual avenues for decoupling aberrant mechanosensing from metabolic dysfunction in certain fibrotic diseases [119]. Second, as established in various specific pathological models, the disruption of ABP-mediated compartmentalization constitutes the structural basis for pathological phenotypes in certain contexts. Aberrant ABP dynamics can lead to the malformation or dissociation of glycolytic metabolons, serving as a juncture where molecular defects translate into cellular dysfunction. In models of diabetic pathologies, for example, hyperglycemic microenvironments induce the O-GlcNAcylation of Profilin, impairing its actin-binding capacity. This disrupts the “GAPDH-Profilin-ATP-actin” channeling unit at the leading edge of migrating fibroblasts, triggering a localized bioenergetic deficit that impairs wound healing [120, 121]. Therapeutic strategies targeting these metabolons are currently being evaluated in preclinical models. Small-molecule Fascin inhibitors can physically dismantle glycolytic enzyme complexes within the invadopodia of tumor cells, causing localized energy starvation and suppressing lung metastasis in models of triple-negative breast cancer [122]. Conversely, in diabetic ulcer models, the topical application of PFKFB3 agonists enhances the localized assembly of glycolytic enzymes with Fascin-actin complexes, promoting fibroblast motility and wound healing [20]. Furthermore, compounds targeting the LLPS interface of ALD-A/GAPDH can selectively dissolve tumor-specific metabolons in vitro, disrupting localized energy supply without significantly affecting the metabolic homeostasis of healthy tissue [123, 124]. Nevertheless, whether these in vitro phase-separation disruptions reliably translate to in vivo efficacy without significant systemic metabolic toxicity remains an open question. Third, evidence suggests that the aberrant assembly of metabolons can drive whole-cell metabolic flux reprogramming. The upregulation of glycolytic flux can amplify the pathological cascade by providing bioenergetic and biosynthetic support for disease progression. A well-documented example is the “Warburg effect” in oncology. Within the TME, HK2 expression in pericytes drives glycolysis, which aberrantly enhances cellular contractility via the ROCK2-MLC2 pathway, ultimately compromising vascular integrity [125]. Moreover, the dysregulation of gluconeogenesis/glycolysis, coupled with aberrant α-actinin4 expression, has been shown to regulate cancer cell differentiation and invasion [126]. Interestingly, in inflammatory conditions like psoriasis, co-culturing normal keratinocytes with psoriatic cells downregulates α-actinin1 while simultaneously upregulating glycolysis and proliferation [127], suggesting a potentially conserved regulatory axis between α-actinins and metabolic states. Therapeutically, certain anti-cancer agents have been shown to suppress bioenergetics to induce the targeted degradation of α-actinins, disrupting the cancer cytoskeletal architecture in defined preclinical settings [128]. Finally, the dysregulation of retrograde metabolite signaling appears to sustain the pathological cycle. As the proposed retrograde arm of this bidirectional loop, aberrant metabolic products reciprocally modulate actin dynamics and mechanical sensing, contributing to the loss of homeostasis. For example, glycolytic uncoupling drives the nuclear translocation of PKM2, where its non-canonical “moonlighting” function interacts with the HIF-1α transcriptional complex to support both glycolysis and invasive programs in cancer cells [129, 130]. In diabetic models, hyperglycemia induces the lysosomal degradation of endothelial PFKFB3, culminating in energy deficit at the angiogenic leading edge [131]. In neurodegenerative contexts, the activation of the synaptic GAPDH-Siah1 apoptotic axis has been linked to neuronal death [132]. Additionally, global energy dysfunction disrupts the intracellular ATP/GTP balance, impairing cytoskeletal dynamics, which manifests as defective cell migration, mitotic catastrophes, and axonal transport failures in various experimental systems [133]. In summary, the dysregulation of the bidirectional “metabolism-cytoskeleton” loop is deeply implicated in the pathogenesis of specific subtypes of cancer, fibrosis, and metabolic complications. Deconstructing disease-specific molecular mechanisms through the lens of this cascade provides a conceptual framework for exploring diagnostic biomarkers and therapeutic vulnerabilities. Currently, while these regulatory paradigms are supported by in vitro models and preclinical animal studies, it remains an unresolved challenge to successfully translate these findings to the clinic. Significant hurdles remain, including target specificity, in vivo spatiotemporal delivery, and potential systemic metabolic toxicity. Moving forward, a deeper, spatiotemporally resolved deconstruction of this mechanometabolic loop across diverse disease contexts has the potential to unveil novel, highly context-dependent therapeutic targets for precision medicine. Conclusions and prospects ABPs serve as key mediators of the mechanometabolic nexus, contributing to a proposed bidirectional feedback cascade: from the initial sensing of mechanical cues and ABP-driven cytoskeletal remodeling to the assembly of glycolytic compartments, metabolic flux alteration, and the subsequent metabolite-driven retrograde control of cell fate. Importantly, while this proposed pathway is assembled from overlapping observations across distinct experimental models and has not yet been validated end-to-end in a single system, this paradigm expands upon traditional models of a purely static cytoskeleton and a diffuse cytosolic energy supply. It provides a useful conceptual framework for understanding the pathogenesis of specific contexts of cancer and organ fibrosis. To delineate the boundaries of existing knowledge within this framework and map out a clear trajectory for future investigations, we have synthesized the core components of this review into an evidence-calibrated matrix (Table 1). This matrix systematically stratifies the literature across five functional domains, explicitly distinguishing directly established preclinical observations from convergent multi-model evidence, conceptual extrapolations, and critical unresolved questions. Addressing the unresolved questions highlighted in this matrix and potentially translating these mechanistic insights into clinical applications will require multidisciplinary approaches. Future research should leverage advanced structural biology (e.g., Cryo-EM) and live-cell biophotonics (e.g., FLIM) to resolve the architecture of ABP-glycolytic assemblies and decode the spatiotemporal rules of bioenergetic flux in complex in vivo environments. Concurrently, although the field has not yet established a unified therapeutic framework across disease categories, translational efforts could eventually explore precision pharmacology. Future strategies may require engineering cell-type-specific delivery systems to maximize tissue selectivity and druggability of this mechanometabolic axis within defined disease models. Ultimately, deeper exploration of this integration may further elucidate the emerging paradigm of “cellular bioenergetic topology”—the concept that where energy is produced is as critical as how much is produced—thereby laying the groundwork for context-dependent therapeutics in diseases driven by mechanometabolic dysregulation Abbreviations Actin-binding proteins Adenosine triphosphate Guanosine triphosphate Actin depolymerizing factor Ezrin-radixin-moesin Hexokinase Phosphofructokinase Phosphoglycerate kinase Glyceraldehyde-3-phosphate dehydrogenase Pyruvate kinase Nicotinamide adenine dinucleotide Pyruvate kinase M2 Hypoxia inducible factor 1 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 Seven in absentia homolog 1 Fructose-6-phosphate Fructose-1, 6-bisphosphate Aldopase Glyceraldehyde-3-phosphate Dihydroxyacetone phosphate Lactate dehydrogenase Enolase 2 Glyceraldehyde-3-phosphate 1,3-bisphosphoglycerate Triose phosphate isomerase Reduction-oxidation Tripartite motif-containing 21 Phosphofructokinase platelet Wiskott-aldrich syndrome protein Integrin beta 8 Tripartite motif-containing 59 Protein kinase B Mammalian target of rapamycin Yes-associated protein Rho associated coiled-coil containing protein kinase Myosin light chain Non-muscle myosin heavy chain IIA Myelocytomatosis oncogene Esophageal squamous cell carcinoma Extracellular matrix Allograft inflammatory factor 1 Phosphoinositide 3-kinase Phosphoglycerate mutase 1 Actin alpha 2 Adenosine diphosphate Reactive oxygen species Alpha smooth muscle actin Actin-like 6 A 2-deoxy-D-glucose Methylglyoxal Transgelin Ras homolog family member A Solute carrier family 2 member 3 Glucose transporter 3 Heat shock protein 70 Triphosphate isomerase Filagrin C Focal adhesion kinases O-linked N-acetylglucosamine Fluorescence lifetime imaging Myosin light chain phosphatase Author contributions ZLZ and NYM contributed to the manuscript and form. NZ and XJW depicted the figure. YWL and CCS modified the grammar. JTZ and XHZ summarized the key enzyme of glycolysis. YSJ and AYW contributed to the conception and design. All authors have read and agreed to the published version of the manuscript. Funding This study was supported by the Liaoning Provincial Science and Technology Project (No.2020JH2/10300143). Data availability Not applicable. Declarations Ethics approval and consent to participate Not applicable. Consent for publication All authors approved the final manuscript and the submission to this journal. Conflict of interest The authors declare that they have no competing financial interests exist. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Ziluo Zhang, Ningye Ma and Nan Zhang are share first authorship. Change history 7/1/2026 Article updated to correct the affiliation Contributor Information Yisheng Jiao, Email: yishengjiao@aliyun.com. Aiyuan Wang, Email: wangay@aliyun.com. References Associated Data Data Availability Statement Not applicable.